Novo hinted at the start of the year at the JP Morgan healthcare conference about M&A deals and whilst we have seen a plethora of deals across a number of Pharma companies
Heres the simplified breakdown: GLP-1 helps suppress appetite GIP supports insulin function and metabolic balance Glucagon may help increase calorie burning and fat utilization That third mechanism may create a stronger overall metabolic effect compared to tirzepatide alone
A Simple fluorometric method for the determination of serum free carnitine
How it Impacts Psychiatric Symptoms Semaglutide, a GLP-1 receptor agonist, enhances insulin secretion and sensitivity
The objective was to evaluate the effectiveness and safety, with a specific focus on cardiovascular safety, of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, compared to insulin glargine in adults with type 2 diabetes and a high risk of cardiovascular events who have not achieved adequate control with oral glucose-lowering medications.This phase 3 study was conducted at 187 sites across 14 countries on five continents
Stone JJ, Prasad NK, Laumonerie P, Howe BM, Amrami KK, Carter JM, et al
